A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-Alcoholic Steatohepatitis

In brief

The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)

Key facts

Study ID

NCT03400163

Run by

Bristol-Myers Squibb

People needed

3

Starts

2015-05-08

Expected to finish

2017-06-19

Last updated by the study team

2021-02-26

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female between 21 and 75 years old
• Body Mass Index (BMI) of 25 or more

You may not qualify if…

• Chronic Liver disease other than NASH
• Uncontrolled diabetes
• Any major surgery within 6 weeks of screening
• Unable to self-administer under the skin injections
• Any bone trauma, fracture or bone surgery within 8 weeks of screening

Where it is running

• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States
• Texas Liver Institute — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.